Drugs News and Research

RSS

Vanderbilt researchers announce multi-national collaboration on Alzheimer's disease genetics

Researchers at Vanderbilt University Medical Center, and across the globe, announced today a multi-national collaboration to discover and map all genes relating to Alzheimer's disease through the formation of the International Genomics of Alzheimer's Project.

1 Feb 2011

Scientists successfully crystallise key norovirus enzyme

With the number of norovirus infection cases rising across the country, scientists from the University of Southampton have successfully crystallised a key norovirus enzyme, which could help in the development of a norovirus treatment.

1 Feb 2011

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

An American dies of heart disease every 39 seconds, and African Americans suffer a higher death rate from heart disease and stroke than Americans overall. Partly as a result of having the highest prevalence of high blood pressure in the world, African Americans have a 1.5 times greater rate of heart disease death than other Americans and a 1.8 times greater rate of fatal stroke.

1 Feb 2011

AstraZeneca and Pfizer support Cancer Research UK in £5.5m Stratified Medicine programme

CANCER RESEARCH UK will be supported by AstraZeneca and Pfizer in a multimillion pound initiative to examine how genetic tests to improve cancer diagnosis can be best rolled out across the NHS.

1 Feb 2011

New method to identify communication pathways connecting distant regions within proteins

A School of Science at Indiana University-Purdue University Indianapolis biophysicist has developed a new method to identify communication pathways connecting distant regions within proteins.

1 Feb 2011

Painless, noninvasive biopsies with smart laser technology

Biopsies in the future may be painless and noninvasive, thanks to smart laser technology being developed at Michigan State University.

1 Feb 2011

FDA approves 'Cornell Dots' for first clinical trial in humans to diagnose cancer

"Cornell Dots" - brightly glowing nanoparticles - may soon be used to light up cancer cells to aid in diagnosing and treating cancer. The U.S. Food and Drug Administration has approved the first clinical trial in humans of the new technology.

1 Feb 2011

Global consortium aims to discover and map all Alzheimer's genes

The launch of the International Genomics of Alzheimer's Project (IGAP) – a collaboration formed to discover and map the genes that contribute to Alzheimer's disease – was announced today by a multi-national group of researchers. The collaborative effort, spanning universities from both Europe and the United States, will combine the knowledge, staff and resources of four consortia that conduct research on Alzheimer's disease genetics.

1 Feb 2011

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Avantra Biosciences today announced the selection of TGen Drug Development as a key test site for Avantra's new biomarker quantitation platform.

1 Feb 2011

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.

1 Feb 2011

PCMA finds Ohio's Medicaid program can save $135 million over the next decade

Ohio's Medicaid program could cost taxpayers an additional $1.6 billion next year, a 49 percent jump in the state's share of costs for the health care program covering more than 2 million poor and disabled Ohioans, according to new information released by the Governor's Office of Health Transformation.

1 Feb 2011

Research on triple negative disease can benefit patients with breat cancer

Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

1 Feb 2011

DNA Direct implements four new health plan clients for molecular diagnostic and genetic tests

DNA Direct, a wholly owned subsidiary of Medco Health Solutions, Inc. and a provider of guidance and decision support for genomic medicine, today announced four new health plan clients that are implementing DNA Direct's Policy & Benefit Support Program for molecular diagnostic and genetic tests.

1 Feb 2011

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Johnson & Johnson's Tibotec Pharmaceuticals unit on Thursday announced it had granted multiple licenses to generic drug manufacturers "to provide copies of [the experimental HIV/AIDS drug rilpivirine hydrochloride] TMC278 in sub-Saharan Africa, India and parts of Asia if it's approved by regulators," Bloomberg Businessweek reports.

1 Feb 2011

Current prevention efforts delay but do not prevent HCV among injection drug users

A recent 20-year study of injection drug users (IDUs) in Baltimore found a significant decline in new cases of HIV infection but only a slight decline in new cases of hepatitis C virus (HCV) infection. The findings suggest that efforts to curb blood-borne transmission of these viral infections have had success but must be expanded against the highly transmissible HCV.

1 Feb 2011

Generics companies weigh in on biological drugs, the Wall Street Journal reports

Generic drug makers are expecting copies of complex biological drugs to become a multi-billion dollar market in the near future.

1 Feb 2011

$FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma$

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Onyx Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma.

1 Feb 2011

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

Maxygen, a biotechnology company focused on the development of improved protein drugs, today announced the initiation of a Phase I clinical study to evaluate a next-generation CTLA4-Ig therapeutic that is being developed by Perseid Therapeutics LLC, Maxygen's majority-owned subsidiary, in collaboration with Astellas Pharma Inc. for the treatment of rheumatoid arthritis and potentially other autoimmune indications.

31 Jan 2011

First Edition: January 31, 2011

KHN staff writers Marilyn Weber Serafini and Julie Appleby report: "Financially strapped governors, Congress and the Obama administration could be headed for a showdown over the Medicaid health care program that covers 48 million poor, disabled and elderly people nationwide".

31 Jan 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

For the first time in the 34-year history of the Empire State Building Run-Up, the New York Road Runners has partnered with a nonprofit as the event's Presenting Sponsor.

31 Jan 2011

Drugs News and Research

Vanderbilt researchers announce multi-national collaboration on Alzheimer's disease genetics

Scientists successfully crystallise key norovirus enzyme

PhRMA: 299 medicines under development for prevention and treatment of heart disease and stroke

AstraZeneca and Pfizer support Cancer Research UK in £5.5m Stratified Medicine programme

New method to identify communication pathways connecting distant regions within proteins

Painless, noninvasive biopsies with smart laser technology

FDA approves 'Cornell Dots' for first clinical trial in humans to diagnose cancer

Global consortium aims to discover and map all Alzheimer's genes

Avantra Biosciences selects TGen Drug Development for new biomarker quantitation platform

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

PCMA finds Ohio's Medicaid program can save $135 million over the next decade

Research on triple negative disease can benefit patients with breat cancer

DNA Direct implements four new health plan clients for molecular diagnostic and genetic tests

Johnson & Johnson deal may bring HIV/AIDS drugs to developing countries faster

Current prevention efforts delay but do not prevent HCV among injection drug users

Generics companies weigh in on biological drugs, the Wall Street Journal reports

FDA grants Onyx fast track designation for carfilzomib in treatment of relapsed and refractory multiple myeloma

Maxygen initiates Phase I study to evaluate CTLA4-Ig therapeutic for treatment of rheumatoid arthritis

First Edition: January 31, 2011

Empire State Building, NYRR partner with MMRF for new myeloma drugs

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News